Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Necitumumab

Necitumumab

Necitumumab (Portrazza®), which received FDA approval on 24 November 2015, is used in disease spread to distant tissues, with squamous cell non-small cell lung cancer patients, together with gemcitabine and cisplatin as first-line treatment. Necitumumab has not been shown to provide benefit in patients with nonsquamous non-small cell lung cancer. Our drug exerts its effect on cancer cells through EGFR (epidermal growth factor receptor).

By inhibiting the functioning of the receptor called EGFR, it prevents cancer cell growth and new blood vessel formation. It also has the ability to kill cancer cells directly. Rash and reduced magnesium levels are its most frequently reported side effects.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Necitumumab

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy